Characterization, stability, and pharmacokinetics of sibutramine/β-cyclodextrin inclusion complex

Journal of Industrial and Engineering Chemistry

Volumn 18, Issue 4, 2012, Pages 1412-1417

  Hwang, Yong Youn ^a,b   Shin, Dong Chul ^b   Nam, Yoon Sung ^a   Cho, Byung Kwan ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b SK Chemicals   (South Korea)

Author keywords

Cyclodextrin; Dissolution; Inclusion complex; Pharmacokinetics; Sibutramine; Stability

Indexed keywords

ACTIVE METABOLITES; AREA UNDER THE CURVES; INCLUSION COMPLEX; PHARMACOKINETIC PARAMETERS; PHARMACOKINETIC PROPERTIES; PHOTOCHEMICAL STABILITY; PLASMA CONCENTRATION; POORLY SOLUBLE DRUGS; SIBUTRAMINE; STANDARD PRODUCTS;

BIOCHEMISTRY; CONVERGENCE OF NUMERICAL METHODS; CYCLODEXTRINS; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; PHARMACOKINETICS; X RAY DIFFRACTION ANALYSIS;

PLASMA STABILITY;

EID: 84862606308     PISSN: 1226086X     EISSN: 22345957     Source Type: Journal    
DOI: 10.1016/j.jiec.2012.01.046     Document Type: Article

References (38)

1. Challa R., Ahuja A., Ali J., Khar R.K. AAPS PharmSciTech 2005, 6:329.
2. Castronuovo G., Niccoli M. Bioorg. Med. Chem. 2006, 14:3883.
3. Loftsson T., Brewster M.E., Masson M. Am. J. Drug. Deliv. 2004, 2:261.
4. Davis M.E., Brewster M.E. Nat. Rev. Drug Discov. 2004, 3:1023.
5. Szejtli J. Pharm. Technol. Int. 1991, 3:15.
6. Brewster M.E., Loftsson T. Adv. Drug Deliv. Rev. 2007, 59:645.
7. Haslam D.W., James W.P.T. Lancet 2005, 366:1197.
8. Rippe J.M., Crossley S., Ringer R. J. Am. Diet. Assoc. 1998, 98(Suppl. 2):S9-S15.
9. Carek P.J., Dickerson L.M. Drugs 1999, 57:883.
10. Jackson H.C., Bearham M.C., Hutchins L.J., Mazurkiewicz S.E., Needham A.M., Heal D.J. Br. J. Pharmacol. 1997, 121:1613.
11. Connoley I.P., Liu Y.L., Frost I., Reckless I.P., Heal D.J., Stock M.J. Br. J. Pharmacol. 1999, 126:1487.
12. McNeely W., Goa K.L. Drugs 1998, 56:1093.
13. Fang H., Senanayake Q., Chris K., Han Z., Morency C., Grover P., Robert E., Bulter M.H., Stephen A., Cameron T.S. Tetrahedron: Asymmetr. 1999, 10:4477.
14. Kim E.J., Park E.K., Suh K.H. Hum. Exp. Toxicol. 2005, 24:109.
15. J.H. Lee, K.S. Park, J.C. Lee, H.K. Kim, Y.K. Jang, K.S. Lee, Patent KR0536750 (2005).
16. Y.J. Chung, Patent KR0618176 (2006).
17. Li D.X., Jang K.Y., Kang W.K., Bae K.J., Lee M.H., Oh Y.K., Jee J.P., Park Y.J., Oh D.H., Seo Y.G., Kim Y.R., Kim J.O., Woo J.S., Yong C.S., Choi H.G. Biol. Pharm. Bull. 2010, 33:279.
18. Lim H.T., Balakrishnan P., Oh D.H., Joe K.W., Kim Y.R., Hwang D.H., Lee Y.B., Yong C.S., Choi H.G. Int. J. Pharm. 2010, 397:225.
19. T.W. Kang, K.J. Jeon, H.J. Shon, W.K. Choi, K.Y. Chang, K.Y. Jin, K.S. Lee, Patent WO090999 (2006).
20. ICH Harmonized Tripartite Guideline 1996. Guidelines for Photostability Testing of New Drug Substance and Products, http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html.
21. Park J.Y., Kim K.A., Park P.W., Suh K.H., Lee G.S. Clin. Ther. 2004, 26:2092.
22. Hind I.D., Mangham J.E., Ghani S.P., Haddock R.E., Garratt C.J., Jones R.W. Eur. J. Clin. Pharmacol. 1999, 54:847.
23. Chen J., Lu W., Zhang Q., Jiang X. J. Chromatogr. B 2003, 785:197.
24. Ding L., Hao X., Huang X., Zhang S. Anal. Chim. Acta 2003, 492:241.
25. ICH Harmonized Tripartite Guideline 1996. Validation of Analytical Procedures: Text and Methodology, http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html.
26. Cheetham S.C., Viggers J.A., Butler S.A., Prow M.R., Heal D.J. Neuropharmacology 1996, 35:63.
27. Gibaldi M., Perrier D. Pharmacokinetics 1982, Marcel-Dekker, New York. second ed.
28. Loftsson T., Brewster M.E. J. Pharm. Sci. 1996, 85:1017.
29. Mielcarek J. Pharmazie 1996, 51:477.
30. Lutka A. Pharmazie 2000, 55:120.
31. Sortino S., Scaiano J.C., De Guidi G., Monti S. Photochem. Photobiol. 1999, 67:603.
32. Polekhina G., Gupta A., van Denderen B.J., Feil S.C., Kemp B.E., Stapleton D., Parker M.W. Structure 2005, 13:1453.
33. Moore J.W., Flanner H.H. Pharm. Technol. 1996, 20:64.
34. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) Guidance for Industry. Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations 1997, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070239.pdf.
35. Cheetham S.C., Viggers J.A., Slater N.A., Heal D.J., Buckett W.R. Neuropharmacology 1993, 32:737.
36. EMEA, 2010. CPMP/EWP/QWP/1401/98 Rev. 1 Corr, Guideline on the Investigation of Bioequivalence, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf.
37. Cheetham S.C., Viggers J.A., Slater N.A., Buckett W.R. Br. J. Pharmacol. 1990, 101:515.
38. Berge S.M., Bighley L.D., Monkhouse D.C. J. Pharm. Sci. 1977, 66:1.